Currently out of the existing stock ratings of Drew Jones, 19 are a BUY (65.52%), 10 are a HOLD (34.48%).

Drew Jones

Work Performance Price Targets & Ratings Chart

Analyst Drew Jones, currently employed at STEPHENS, carries an average stock price target met ratio of 95.45% that have a potential upside of 32.79% achieved within 423 days. Previously, Drew Jones worked at DEUTSCHE BANK.

Drew Jones’s has documented 62 price targets and ratings displayed on 12 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on LGND, Ligand Pharmaceuticals at 03-May-2019.

Wall Street Analyst Drew Jones

Analyst best performing recommendations are on EXAS (EXACT SCIENCES).
The best stock recommendation documented was for EXAS (EXACT SCIENCES) at 10/31/2017. The price target of $54 was fulfilled within 1 day with a profit of $0.99 (1.8%) receiving and performance score of 18.

Average potential price target upside

of $19.42 (25.51%) on LGND (LIGAND PHARMACEUTICALS).
of $8.33 (28.82%) on AZTA (AZENTA).
of $8.24 (21.41%) on RGEN (REPLIGEN).

EXAS EXACT Sciences LGND Ligand Pharmaceuticals MYGN Myriad Genetics AZTA Azenta BRKS Brooks Automation CERS Cerus CTLT Catalent OSUR OraSure Technologies PACB Pacific Biosciences of California RGEN Repligen TECH Bio-Techne Corp VCYT Veracyte

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Mark Massaro (BTIG)